Onconova Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Onconova Therapeutics generated cash of -$17,932,000, which is less than the previous year. Cash used in financing activities reached the amount of -$17,935,982,064,000 last year. Net change in cash is therefore -$17,936,000.
Cash Flow
| 2014 | -57.64M | 39.77M | 1.46M |
|---|---|---|---|
| 2015 | -31.23M | 0 | 7.46M |
| 2016 | -15.81M | 0 | 17.42M |
| 2017 | -23.82M | 0 | 6.36M |
| 2018 | -22.69M | 0 | 35.65M |
| 2019 | -20.83M | -55K | 26.64M |
| 2020 | -23.07M | -15K | 19.35M |
| 2021 | -19.48M | 0 | 55.56M |
| 2022 | -16.29M | 0 | 0 |
| 2023 | -17.93M | -14K | -17.93T |
ONTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 38.75M | 55.07M | 19.02M | 22.72M | 16.97M | 4.02M | 21.45M | 19.79M | 43.58M | 60.00M |
Operating activities | ||||||||||
Net income | -18.94M | -18.96M | -16.16M | -25.15M | -21.50M | -20.41M | -24.09M | -19.66M | -24.02M | -63.79M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 16K | 14K | 14K | 13K | 14K | 55K | 88K | 96K | 150K | 434K |
Stock-based compensation expense | 1.30M | 1.17M | 576K | 369K | 1.04M | 1.14M | 1.71M | 3.92M | 3.78M | 5.06M |
| Deferred income tax benefit | 1.30M | 1.17M | 576K | 369K | 1.04M | 1.14M | 1.71M | 3.92M | 3.78M | 5.06M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 11B | -1K | 9B | 61K | -63B | 24B | -28B | 1.47M | -1.37M | 0 |
Inventories | -11.00B | 0 | -9B | -61K | 63B | -23.99B | 27.99B | 897K | -814K | 0 |
Accounts payable | 1.75M | 1.10M | -2.07M | 562K | 232K | -1.45M | 863K | 1.90M | -606K | 317K |
Cash generated by operating activities | -17.93M | -16.29M | -19.48M | -23.07M | -20.83M | -22.69M | -23.82M | -15.81M | -31.23M | -57.64M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -14K | 0 | 0 | -15K | -55K | 0 | 0 | 0 | 0 | -228K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -14K | 0 | 0 | -15K | -55K | 0 | 0 | 0 | 0 | 39.77M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 55.04M | 9.06M | 21.75M | 0 | 6.36M | 17.42M | 7.46M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -17.93T | 0 | 55.56M | 19.35M | 26.64M | 35.65M | 6.36M | 17.42M | 7.46M | 1.46M |
Net Change In Cash | -17.93M | -16.31M | 36.04M | -3.70M | 5.75M | 12.94M | -17.42M | 1.60M | -23.78M | -16.42M |
Cash at end of period | 20.82M | 38.75M | 55.07M | 19.02M | 22.72M | 16.97M | 4.02M | 21.4M | 19.79M | 43.58M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |